Actively Recruiting

Phase 1
Phase 2
Age: 6Months - 21Years
All Genders
NCT05334693

Expanded Haploidentical Natural Killer Cells as Consolidation Strategy for Children/Young Adults With AML

Led by Belarusian Research Center for Pediatric Oncology, Hematology and Immunology · Updated on 2024-08-28

15

Participants Needed

1

Research Sites

239 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The purpose of this study is to estimate the efficacy of immunotherapy with ex vivo expanded haploidentical NK cells as consolidation therapy for children/young adults with intermediate risk AML.

CONDITIONS

Official Title

Expanded Haploidentical Natural Killer Cells as Consolidation Strategy for Children/Young Adults With AML

Who Can Participate

Age: 6Months - 21Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients with primary intermediate risk AML in molecular complete remission
  • Patients with primary high risk AML in molecular complete remission awaiting unrelated hematopoietic stem cell transplantation
  • Karnofsky or Lansky performance score of 70 or higher
  • Written informed consent from patient or guardian
  • Haploidentical family donor available
  • Donor suitable for cell donation and apheresis according to standard criteria
  • Written informed consent from donor
Not Eligible

You will not qualify if you...

  • Uncontrolled infection in patient
  • Severe liver dysfunction with SGOT or SCPT 5 times or more above the upper limit for age
  • Positive serology for HIV in patient
  • Donor pregnancy
  • Donor positive serology for HIV, hepatitis B, or hepatitis C

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Belarussian Research Center for Pediatric Oncology, Hematology and Immunology

Minsk, Minsk Oblast, Belarus, 223053

Actively Recruiting

Loading map...

Research Team

T

Tatsiana Shman, PhD

CONTACT

M

Mariya Naumovich, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Expanded Haploidentical Natural Killer Cells as Consolidation Strategy for Children/Young Adults With AML | DecenTrialz